News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
283,750 Results
Type
Article (14640)
Company Profile (39)
Press Release (269071)
Section
Business (80409)
Career Advice (1321)
Deals (15949)
Drug Delivery (32)
Drug Development (48327)
Employer Resources (54)
FDA (7701)
Job Trends (6464)
News (150968)
Policy (12595)
Tag
Academia (993)
Alliances (14993)
Alzheimer's disease (616)
Antibody-drug conjugate (ADC) (46)
Approvals (7678)
Artificial intelligence (66)
Bankruptcy (111)
Best Places to Work (5581)
Breast cancer (98)
Cancer (784)
Cardiovascular disease (60)
Career advice (1026)
Cell therapy (138)
Clinical research (40680)
Collaboration (218)
Compensation (119)
COVID-19 (1179)
C-suite (45)
Data (859)
Diabetes (95)
Diagnostics (2553)
Earnings (49152)
Employer resources (48)
Events (45331)
Executive appointments (149)
FDA (8047)
Funding (196)
Gene therapy (102)
GLP-1 (351)
Government (1629)
Healthcare (8062)
Infectious disease (1226)
Inflammatory bowel disease (51)
Interviews (247)
IPO (9539)
Job creations (1182)
Job search strategy (909)
Layoffs (166)
Legal (2013)
Lung cancer (120)
Manufacturing (86)
Medical device (5761)
Medtech (5761)
Mergers & acquisitions (6531)
Metabolic disorders (247)
Neuroscience (787)
NextGen Class of 2024 (2409)
Non-profit (2079)
Northern California (973)
Obesity (130)
Opinion (79)
People (12871)
Phase I (10027)
Phase II (16707)
Phase III (17373)
Pipeline (423)
Postmarket research (1369)
Preclinical (3363)
Radiopharmaceuticals (118)
Rare diseases (119)
Real estate (1525)
Regulatory (9601)
Research institute (916)
Resumes & cover letters (255)
Southern California (826)
Startups (1074)
United States (7695)
Vaccines (287)
Weight loss (83)
Date
Last 7 days (462)
Last 30 days (2508)
Last 365 days (20277)
2024 (18767)
2023 (21226)
2022 (25568)
2021 (26883)
2020 (25282)
2019 (20187)
2018 (15167)
2017 (15632)
2016 (13557)
2015 (16116)
2014 (11829)
2013 (8845)
2012 (9257)
2011 (9743)
2010 (8375)
Location
Africa (373)
Asia (20138)
Australia (3759)
California (2081)
Canada (686)
China (160)
Colorado (89)
Connecticut (100)
Delaware (57)
Europe (41308)
Florida (255)
Georgia (65)
Illinois (159)
Indiana (112)
Japan (56)
Kansas (49)
Maryland (271)
Massachusetts (1474)
Michigan (54)
Minnesota (146)
New Jersey (620)
New York (578)
North Carolina (377)
Northern California (973)
Ohio (68)
Pennsylvania (467)
South America (541)
Southern California (826)
Texas (275)
Utah (48)
Washington State (223)
283,750 Results for "3".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Roche Wins First-Line Breast Cancer Nod for Oral PI3K Blocker, Projects $2.3B in Peak Sales
With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K inhibitor Piqray, which last year generated $505 million in revenue.
October 11, 2024
·
2 min read
·
Tristan Manalac
3 Major Product Releases at 3Shape Discover Event
3Shape announces the launch of three exciting solutions at its 3Shape Discover digital dentistry event.
June 7, 2024
·
3 min read
Podcast
Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More
Pfizer, Sanofi and others report Q3 beats; AbbVie, Roche and Novartis strike big deals; the 2024 presidential election looms; and
BioSpace
takes a look back at 10 years of NextGen, our annual pick of young biotechs to watch.
October 30, 2024
·
1 min read
·
Heather McKenzie
Earnings
Sanofi Beats Q3 Forecasts Fueled by 381% Growth in Beyfortus Sales
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, bringing in almost $700 million in the third quarter. Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3.
October 25, 2024
·
3 min read
·
Tristan Manalac
Press Releases
Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a new game changer in the bone field
At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete bone healing Derived from Novadip’s 3M3 stem cell platform, NVDX3, a unique ‘off-the-shelf allogeneic matrix product to cure common but challenging orthopedic conditions, has potential to replace existing allogeneic bone substitutes to heal fractures
October 18, 2024
·
1 min read
Earnings
J&J Gets Q3 Beat, Raises Full-Year Guidance on Strong Darzalex Sales
Sales of Johnson & Johnson’s oncology drugs jumped nearly 19% in the third quarter, driven by cancer treatment Darzalex which brought in more than $3 billion.
October 15, 2024
·
2 min read
·
Tristan Manalac
DLL3 Targeted Therapies Clinical Trials Insight
Delta-like ligand 3 (DLL3) has emerged as an exciting target for precision cancer medicine. DLL3 is a protein expressed during fetal development that is involved in regulating cell differentiation.
May 21, 2024
·
2 min read
Podcast
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona comes at a bad time for the company; Sen. Warren calls for scrutiny of Novo’s purchase of Catalent; and other news.
October 16, 2024
·
1 min read
·
Heather McKenzie
Drug Development
Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301
Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury during percutaneous coronary intervention (PCI), today announced completion of enrollment in its ongoing pivotal Phase 3 Iocyte AMI-3 trial of FDY-5301.
June 11, 2024
·
3 min read
Press Releases
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
October 30, 2024
·
11 min read
1 of 28,375
Next